We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Percentage of Secondary Prevention Patients Treated to Their LDL-C Targets

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00536796
First Posted: September 28, 2007
Last Update Posted: October 30, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
AstraZeneca
  Purpose
A cholesterol/lipid profile screening project of high risk patients with hyperlipidaemia (secondary prevention) who already receive cholesterol-lowering therapy. Lipid profile and rate of patients who are treated to target (which is <100mg/dl for patients with high risk and <70mg/dl for patients at very high risk) are screened (hospital-based specialists). The doctors therapy decisions after the screening and possible reasons for these decisions will be documented. Our aim is to evaluate dosing habits, to evaluate how many patients are treated to their LDL-C target and to underline the importance of treating patients to their cholesterol targets.

Condition
Hyperlipidemias Atherosclerosis Coronary Heart Disease Carotid Stenosis Peripheral Vascular Diseases Diabetes Mellitus

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Non-interventional Study Investigating How Effective Secondary Prevention Patients Are Treated to Their LDL-C Targets

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Cholesterol levels [ Time Frame: After 4 weeks ]
    Cholesterol levels from high risk patients after 4 weeks of cholesterol-lowering drug therapy under target values


Enrollment: 1096
Study Start Date: September 2007
Study Completion Date: December 2007
Primary Completion Date: December 2007 (Final data collection date for primary outcome measure)
Groups/Cohorts
Patients at very high risk
Patients at high risk
Patients at medium risk
Patients at low risk

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Male and female secondary prevention patients with: coronary disease with event: acute coronary syndrome, status post MI, PTCA, CABG, angiographically verified), PAVK (min. IIb or S.p. revascularization), stroke/TIA, carotis-plaque (asymptomatic min. 70% or S.p. revascularization), Diabetes Mellitus (type I, II)
Criteria

Inclusion Criteria:

  • Secondary prevention patients with hyperlipidemia and atherosclerosis (coronary heart disease, carotid stenosis, PVD, etc.) and/or diabetes who already receive cholesterol-lowering therapy

Exclusion Criteria:

  • Patients who do not receive cholesterol-lowering therapy
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00536796


Locations
Austria
Research Site
Rohrbach, Upper Austria, Austria
Sponsors and Collaborators
AstraZeneca
Investigators
Study Chair: Josef Patsch, MD Chair of the Austrian Atheroslerosis Society
Study Chair: Bernhard Foger, MD Co-Chair of the Austrian Atheroslerosis Society
  More Information

Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT00536796     History of Changes
Other Study ID Numbers: NIS-CAT-CRE-2007/2
First Submitted: September 27, 2007
First Posted: September 28, 2007
Last Update Posted: October 30, 2014
Last Verified: October 2014

Keywords provided by AstraZeneca:
Hyperlipidemia
Need-to-treat
NIS
Secondary prevention patients with hyperlipidemia and atherosclerosis (coronary heart disease, carotid stenosis, PVD, etc.) and/or diabetes

Additional relevant MeSH terms:
Diabetes Mellitus
Heart Diseases
Atherosclerosis
Coronary Disease
Coronary Artery Disease
Myocardial Ischemia
Vascular Diseases
Hyperlipidemias
Hyperlipoproteinemias
Peripheral Vascular Diseases
Peripheral Arterial Disease
Carotid Stenosis
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Cardiovascular Diseases
Arteriosclerosis
Arterial Occlusive Diseases
Dyslipidemias
Lipid Metabolism Disorders
Carotid Artery Diseases
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases